Company / Gross Profit
Gilead Sciences Gross Profit History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$4.2B
FY2019
5-year range
-
FY2016-FY2019
Trend
+6.1%
vs FY2018
Sector context
#5 of 29
Health Care
What the data says
Gilead Sciences's gross profit of $4.2B is higher than 83% of companies in the Health Care sector (FY2019). Gross Profit returned to growth in FY2019 after 2 years of decline, reaching $4.2B.
Based on SEC 10-K filings.
$4.2B in FY2019 with a 3-year CAGR of -13.2%. Top quartile in the Health Care sector.
Declined from $5.4B to $4.2B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -13.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 29This company $4.2B Sector average $3.5B
▼
+22.6% above sector average
Key checks
Key Insights
- 3-year CAGR of -13.2%, indicating a declining trend.
- In FY2019, gross profit increased 6.1% year-over-year.
- Ranks #5 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $4.2B | +6.1% |
| FY2018 | $4.0B | -26.2% |
| FY2017 | $5.4B | -16.5% |
| FY2016 | $6.5B | -0.5% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026